Skip to main content
Premium Trial:

Request an Annual Quote

Twist Bioscience Announces $100M Public Stock Offering

NEW YORK – Twist Bioscience said Tuesday after the close of the market that it intends to sell up to $100 million of its common stock in an underwritten public offering.

Twist said it plans to use the proceeds to invest in its research and development organization, including pharmaceutical biologics drug discovery and DNA data storage; to scale its next-generation sequencing commercial operations; and to expand its production capacity. The company will also use the funds for working capital and general corporate purposes. 

JP Morgan, Cowen, and Evercore Group are acting as joint book-running managers and Robert W. Baird as lead manager.

In December, Twist entered into an agreement with Cowen to sell up to $50 million in stock, following a shelf registration filed with the US Securities and Exchange Commission in November. Twist also completed an offering of approximately 2.2 million shares of common stock in January, raising about $48.2 million. The company went public in October 2018 with an initial $86.3 million offering and raised an additional $84 million in May 2019. 

Twist intends to grant the underwriters a 30-day option to purchase up to $15 million worth of its common stock.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.